Announcements Trials
Browse Landscape

Phase

Phase 2 10Phase 1 9Phase NA 3Phase EARLY_PHASE1 1Phase 4 1Phase 1/2 1

Status

Unknown 2Terminated 2Recruiting 2Completed 2Withdrawn 1Enrolling by invitation 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Breast Neoplasms 16Neoplasms 11Pancreatic Neoplasms 10Prostatic Neoplasms 7Glioma 6Squamous Cell Carcinoma of Head and Neck 5Ovarian Neoplasms 5Head and Neck Neoplasms 5Glioblastoma 5Carcinoma, Non-Small-Cell Lung 5Triple Negative Breast Neoplasms 4Sarcoma 4Polycystic Ovary Syndrome 4Colonic Neoplasms 4Obesity 3Neoplasm Metastasis 3Multiple Myeloma 3Melanoma 3Lymphoma 3Lung Neoplasms 3Carcinoma, Intraductal, Noninfiltrating 3Brain Neoplasms 3Pain, Postoperative 2Fallopian Tube Neoplasms 2Esophageal Neoplasms 2Endometrial Neoplasms 2Depression 2Cholangiocarcinoma 2Central Nervous System Neoplasms 2Carcinoma, Renal Cell 2

Interventions

ruxolitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Withdrawn × Carcinoma, Squamous Cell × Clear all
NCT02593929 2017-06-08

Pharmacodynamic Effects and Predictive Biomarkers With Ruxolitinib in Operable Head and Neck Cancer

University of Pittsburgh

Phase EARLY_PHASE1 Withdrawn
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡